Table 2.
Information of ongoing clinical trials registered in clinicaltrials.gov.
| Target antigen | Disease | Phase | Clinical trial identifier code* |
|---|---|---|---|
| Clinical trials of hematological malignancies | |||
| CD19 | Leukemia | 1 or 2 |
NCT02975687, NCT03097770, NCT03208556, NCT03016377, NCT03263208, NCT03064269, NCT02924753, NCT03142646, NCT03391739 |
| Lymphoma | 1 or 2 |
NCT03029338, NCT02081937, NCT03146533, NCT02842138, NCT03208556, NCT02652910 |
|
| Lymphoma and leukemia | 1 or 2 |
NCT02819583, NCT03383952, NCT03271515, NCT03110640 |
|
| CD20 | Leukemia and lymphoma | 1 or 2 | NCT02710149 |
| Lymphoma | 2 |
NCT03277729, NCT02965157 |
|
| CD19 and CD20 | Leukemia and lymphoma | 1 |
NCT03097770, NCT03019055 |
| Lymphoma | 1 or 2 | NCT03207178 | |
| CD22 | Leukemia and lymphoma | 2 | NCT02935153 |
| Lymphoma | 1 | NCT03244306 | |
| CD19 and CD22 | Leukemia and lymphoma | 1 or 2 |
NCT03233854, NCT03185494, NCT03098355 |
| CD30 | Lymphoma | 1 |
NCT03383965, NCT03049449 |
| BCMA | Multiple myeloma | 1 or 2 |
NCT03287804, NCT03288493, NCT03070327, NCT03338972, NCT03322735, NCT03380039 |
| CD123 | AML | 1 | NCT03114670 |
| BPDCN | 1 | NCT03203369 | |
| CD33 | Leukemia and lymphoma | 1 | NCT03126864 |
| Ig k | Lymphoma | 1 | NCT00881920 |
| Myeloma | |||
| Leukemia | |||
| ROR1 | Breast | 1 | NCT02706392 |
| Lung | |||
| Acute lymphoblastic leukemia | |||
| Chronic lymphoblastic leukemia | |||
| Lymphoma | |||
| Clinical trial of solid tumors | |||
| EGFR | Sarcoma | 1 | NCT00902044 |
| Glioblastoma | 1 | NCT02442297 | |
| Glioblastoma multiform (GBM) | 1 | NCT02844062 | |
| Recurrent GBM | 1 | NCT03283631 | |
| Recurrent brain tumors | |||
| EGFR-positive colorectal cancer | 1 or 2 | NCT03152435 | |
| Advanced solid tumor | 1 or 2 | NCT03182816 | |
| Advanced solid tumor | 1 or 2 | NCT02873390 | |
| EGFRvIII | Glioblastoma | 1 | NCT02664363 |
| GBM | 1 | NCT02844062 | |
| Malignant glioma | 1 or 2 | NCT01454596 | |
| Brain cancer | |||
| Pancreatic cancer | 1 | NCT03267173 | |
| HER2 | HER2 positive cancers | 1 or 2 | NCT02713984 |
| Glioblastoma | 1 | NCT02442297 | |
| Sarcoma | 1 | NCT00902044 | |
| Mesothelin | Advanced solid tumor | 1 or 2 | NCT03182803 |
| Mesothelin positive tumors | 1 | NCT02930993 | |
| Advanced solid tumor | 1 or 2 | NCT03030001 | |
| Pancreatic cancer | 1 or 2 | NCT01583686 | |
| Cervical cancer | |||
| Ovarian cancer | |||
| Mesothelioma | |||
| Lung cancer | |||
| Cervical cancer | 1 or 2 | NCT03356795 | |
| Pancreatic cancer | 1 | NCT03323944 | |
| Malignant pleural disease | 1 | NCT02414269 | |
| Breast cancer | |||
| Lung cancer | |||
| Mesothelioma | |||
| Pancreatic cancer | 1 | NCT02706782 | |
| Breast cancer | 1 | NCT02792114 | |
| Hepatocellular | 1 or 2 | NCT02959151 | |
| Pancreatic cancer metastatic | |||
| Colorectal cancer metastatic | |||
| PSMA | Cervical cancer | 1 or 2 | NCT03356795 |
| Urothelial bladder carcinoma | 1 or 2 | NCT03185468 | |
| Bladder cancer | |||
| Prostate cancer | 1 | NCT03089203 | |
| CD70 | Pancreatic cancer | 1 or 2 | NCT02830724 |
| Breast cancer | |||
| Ovarian cancer | |||
| Renal cell cancer | |||
| Melanoma | |||
| MUC1 | Lung cancer | 1 | NCT03198052 |
| Non-small cell lung cancer | 1 or 2 | NCT02587689 | |
| Triple-negative invasive breast carcinoma | |||
| Hepatocellular carcinoma | |||
| Pancreatic carcinoma | |||
| Advanced solid tumor | 1 or 2 | NCT03179007 | |
| Gastric carcinoma | 1 or 2 | NCT02617134 | |
| Colorectal carcinoma | |||
| Malignant glioma of brain | |||
| Lung cancer | 1 or 2 | NCT03356808 | |
| Cervical cancer | 1 or 2 | NCT03356795 | |
| Sarcoma | 1 or 2 | NCT03356782 | |
| Osteoid sarcoma | |||
| Ewing sarcoma | |||
| Pancreatic cancer | 1 | NCT03267173 | |
| GD2 | Neuroblastoma | 1 or 2 | NCT03373097 |
| Neuroblastoma | 1 or 2 | NCT02765243 | |
| Cervical cancer | 1 or 2 | NCT03356795 | |
| Relapsed or refractory neuroblastoma | 1 | NCT02761915 | |
| CEA | Colorectal cancer | 1 | NCT02349724 |
| Breast cancer | |||
| Lung cancer | |||
| Pancreatic cancer | |||
| Gastric cancer | |||
| GPC3 | Lung squamous cell carcinoma | 1 | NCT02876978 |
| Hepatocellular carcinoma | 1 | NCT03198546 | |
| Squamous cell lung cancer | |||
| Hepatocellular carcinoma | – | NCT03146234 | |
| Hepatocellular carcinoma | 1 or 2 | NCT03130712 | |
| Hepatocellular carcinoma | 1 or 2 | NCT02715362 | |
| MET | Malignant melanoma | 1 | NCT03060356 |
| Breast cancer | |||
| PD-L1 | Non-small cell lung cancer | 1 | NCT03060343 |
| Advanced lung cancer | 1 | NCT03330834 | |
| Lung cancer | 1 | NCT03198052 | |
BMCA, B-cell maturation antigen; Ig, immunoglobin; ROR1, receptor tyrosine kinase-like orphan receptor; MUC, mucin; EGFRvIII, EGFR variant III; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; GPC3, glypican 3; CEA, carcinoembryonic antigen; PSMA, prostate-specific membrane antigen; PD-L1, programmed death-ligand 1; PD-1, programmed death-1.
*Data of ongoing clinical trials are confirmed by clinicaltrials.gov.